SEC Comment Letter 0000000000-22-012476 to INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)

INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)
Date: Nov. 17, 2022 · CIK: 0001292519 · Accession: 0000000000-22-012476

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-268256

Date

November 17, 2022

Author

Not clearly detected

Form

UPLOAD

Company

INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)

Letter

United States securities and exchange commission logo November 17, 2022 Richard Toselli President and Chief Executive Officer InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 Re:InVivo Therapeutics Holdings Corp. Registration Statement on Form S-1 Filed November 9, 2022 File No. 333-268256 Dear Richard Toselli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jordan Nimitz at 202-551-5831 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Rosemary G. Reilly, Esq.

Show Raw Text

United States securities and exchange commission logo
November 17, 2022
Richard Toselli
President and Chief Executive Officer
InVivo Therapeutics Holdings Corp.
One Kendall Square, Suite B14402
Cambridge, MA 02139
Re:InVivo Therapeutics Holdings Corp.
Registration Statement on Form S-1
Filed November 9, 2022
File No. 333-268256
Dear Richard Toselli:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jordan Nimitz at 202-551-5831 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Rosemary G. Reilly, Esq.

SecProbe.io